Safety Study of CTS21166 to Treat Alzheimer Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: CTS21166 (ZPQ-21166)
- Registration Number
- NCT00621010
- Lead Sponsor
- CoMentis
- Brief Summary
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 56
Inclusion Criteria
- Healthy adult male > age 21;
- non-smoker (minimum 6 months);
Exclusion Criteria
- History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease
- History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
- Participation in another clinical trial within 30 days prior to dosing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort CTS21166 (ZPQ-21166) -
- Primary Outcome Measures
Name Time Method To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration
- Secondary Outcome Measures
Name Time Method To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma
Trial Locations
- Locations (1)
Lifetree Clinical Research
🇺🇸Salt Lake City, Utah, United States